Trevena Investor Relations Material
Latest events
Q3 2023
Trevena
Q3 2024
7 Nov, 2024
Q2 2024
8 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Trevena Inc
Access all reports
Trevena Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines targeted at central nervous system (CNS) disorders. The company's portfolio includes OLINVYK (oliceridine) injection, which is approved for use in adults to manage acute pain severe enough to require an intravenous opioid analgesic when alternative treatments are inadequate. Trevena also has several investigational drug candidates in its pipeline. The company is headquartered in Chesterbrook, Pennsylvania, and its shares are listed on the NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
TRVN
Country
🇺🇸 United States